**David Malek**

**Partner, Pivotal bioVentures**

David Malek is a Partner with Pivotal bioVentures, a life sciences venture capital fund based in San Francisco and Boston. John Doe is an investment professional with over 15 years of experience across big pharma, biotech and venture capital. In his current role he is responsible for identifying and leading new investments out of Pivotal’s latest fund, as well as managing the investment in some of the 25 portfolio companies the fund currently has. Prior to joining Pivotal he was the Chief Business Officer at BioLineRx (NASDAQ: BLRX), a drug development company, and prior to that David held a variety of leadership roles at Sanofi (NASDAQ: SNY), mainly in corporate and business development functions. David serves on the board of directors of Avalyn Pharma, Aptihealth and Encodia. David earned his MBA at the Tuck School of Business at Dartmouth, and his B.A. in Statistics from the University of Haifa.